CClinicalTrials.gg
Active, not recruitingNCT03478566Updated Apr 11, 2023

Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease

An interventional study of Transcutaneous CO2 monitoring in Sleep Disorder; Breathing-Related, Central Apnea and Neuromuscular Diseases, sponsored by The Hospital for Sick Children. Active, not recruiting at 1 site in Canada. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

There is an unmet demand for the evaluation of nocturnal hypoventilation in children with NMD. An ambulatory screening tool that can reliably facilitate timely diagnosis and treatment in these children would be invaluable. If an ambulatory, at home, tcCO2 monitoring device is shown to be diagnostically accurate, sleep physicians would be able to triage children on existing waiting lists and optimize screening of nocturnal hypoventilation as recommended by international guidelines.

02

Conditions studied

  • Sleep Disorder; Breathing-Related
  • Central Apnea
  • Neuromuscular Diseases
  • Obstructive Sleep Apnea
03

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • children with a confirmed diagnosis of NMD that meet criteria for evaluating SDB as per international recommendations
  • lives within the greater Toronto area.

Exclusion criteria

Exclusion Criteria:

  • known diagnosis of nocturnal hypoventilation
  • current ventilatory support
  • physician diagnosis of active upper respiratory tract infection (fever, increased cough, rhinorrhea, increased nasal congestion, sore throat, headache, malaise and/or sneezing).
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Transcutaneous CO2 monitoring

    Device: Transcutaneous CO2 monitoring

Interventions

  • DeviceTranscutaneous CO2 monitoring

    The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).

05

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of ambulatory, at home, transcutaneous CO2 (tcCO2) monitoring to diagnose nocturnal hypoventilation as compared to the gold standard, end tidal CO2 conducted during polysomnogram (PSG).

    Time frame: 9 months

Secondary outcomes

  1. a) Agreement of tcCO2 monitoring when worn in the ambulatory, at home, setting compared to tcCO2 recorded during a PSG in a hospital based sleep laboratory for diagnosis of nocturnal hypoventilation.

    b) Correlation of the pre and post sleep capillary blood gas results with end tidal CO2 (etCO2) and tcCO2 recordings during PSG.

    Time frame: 9 months

06

Study locations

1 site
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03478566
Lead sponsor
The Hospital for Sick Children
Responsible party
Reshma Amin (Staff Physician, The Hospital for Sick Children) — Principal investigator
First posted
Mar 27, 2018
Start date
Oct 1, 2018
Primary completion
Dec 31, 2021
Completion
Sep 1, 2023 (estimated)
Last update
Apr 11, 2023

Study contacts

Reshma Amin, MD
principal investigator · Staff Physician

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion